Epidemiological survey of patients with pustular psoriasis in the Japanese Society for Psoriasis Research from 2017 to 2020.
Japan
Japanese Society for Psoriasis Research
dermatology
epidemiology
pustular psoriasis
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
02
08
2022
accepted:
30
08
2022
pubmed:
25
9
2022
medline:
4
1
2023
entrez:
24
9
2022
Statut:
ppublish
Résumé
The Japanese Society for Psoriasis Research (JSPR) has been conducting annual epidemiological surveys of patients with pustular psoriasis in Japan since 2017. This study aimed to conduct a recent epidemiological analysis of patients with pustular psoriasis who were enrolled in the JSPR from 2017 to 2020. A total of 291 patients from 131 medical institutions were enrolled, of which 47.4% (138 cases) were males and 52.6% (153 cases) were females. The mean ± standard deviation (SD) age of the patients was 57.4 ± 20.3 years (males, 61.2 ± 17.3 years; females, 54.1 ± 22.1 years). The mean ± SD age of the patients at disease onset was 48.5 ± 22.5 years (males, 50.8 ± 20.6 years; females, 46.4 ± 24.0 years). The types of pustular psoriasis observed included the von Zumbusch type (59.8%), annular pustular psoriasis (8.2%), impetigo herpetiformis (6.5%), and acrodermatitis continua of Hallopeau (4.8%), of which, the majority of the patients with impetigo herpetiformis were female. Among the patients, 58.4% were treated with oral medications and 44.0% were treated with biologics. The most common oral medication prescribed was etretinate (52.4%), followed by corticosteroids (24.7%) and cyclosporin (22.9%). The most common biologics used were IL-17 inhibitors (ixekizumab [28.1%] and secukinumab [22.7%]), followed by tumor necrosis factor (TNF) inhibitors (infliximab [15.6%]) and IL-23 inhibitors (guselkumab [14.8%] and risankizumab [10.2%]). This survey thus provides new and significant information regarding the recent perspective of pustular psoriasis, such as patient characteristics and treatment trends, in Japan.
Identifiants
pubmed: 36152301
doi: 10.1111/1346-8138.16583
pmc: PMC10087399
doi:
Substances chimiques
Etretinate
65M2UDR9AG
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3-11Informations de copyright
© 2022 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
Références
Acta Derm Venereol. 1996 Jan;76(1):68-71
pubmed: 8721499
J Dermatol. 1999 Mar;26(3):141-9
pubmed: 10209919
Int J Dermatol. 2014 Jun;53(6):676-84
pubmed: 23967807
J Dermatol. 2021 Oct;48(10):1463-1473
pubmed: 34212422
J Dermatol. 2021 Sep;48(9):1336-1342
pubmed: 34018629
J Dermatol. 2018 Mar;45(3):293-301
pubmed: 29115687
JAAD Int. 2022 Jan 12;6:61-67
pubmed: 35059660
J Am Acad Dermatol. 2022 Jun;86(6):1266-1274
pubmed: 34116101
J Dermatol Sci. 2014 Jun;74(3):187-92
pubmed: 24656634
J Dermatol. 2023 Jan;50(1):3-11
pubmed: 36152301
J Dermatol. 2022 Jan;49(1):142-150
pubmed: 34723399
J Dermatol. 2018 Nov;45(11):1235-1270
pubmed: 30230572
J Dermatol. 2011 Dec;38(12):1125-9
pubmed: 21951304
Expert Rev Clin Immunol. 2019 Sep;15(9):907-919
pubmed: 31486687
Lancet. 2021 Apr 3;397(10281):1301-1315
pubmed: 33812489
Int J Mol Sci. 2018 Jun 27;19(7):
pubmed: 29954107
J Dermatol. 2021 Jun;48(6):864-875
pubmed: 33580908
Int J Mol Sci. 2019 Sep 05;20(18):
pubmed: 31491865
J Dermatol Sci. 2003 Feb;31(1):59-64
pubmed: 12615365